PharmaCyte Biotech Inc (PMCB)

[Mens et Manus]

It looks like Q3, 2016 is the new target date for the PC human trial. I hope this is the final timeline otherwise they will run out of time and money. See below....


The Company currently has approximately $3.0M in cash on hand (and no debt), which management estimates is sufficient to run
operations for the next 12 months. We estimate that the Phase 2b trial costs could range from approximately $4 – 6 million and take up to a
year to a year and a half, with data readouts at the six-month mark. With very lean overhead and a reliance on contractors for the majority
of its R&D, we believe that PharmaCyte can maintain its cost levels in areas outside the clinic. We note that a milestone with SG Austria for
$100K could be reached in Q3 CY16, as the first human patient comes into play as part of the clinical trial for pancreatic cancer.